News

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

Discussing the need to identify an effective first-line treatment, the director of the Pediatric Headache Program at CHOP further discussed treatment adherence in this patient population. [WATCH TIME: 5 minutes]

The risk of 5-year ipsilateral recurrent stroke was 14.3% for those with Symptomatic Carotid Atheroma Inflammation Lumen-Stenosis scores of at least 3 compared with 2.6% for those with low-risk category scores.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center gave her expert opinion on whether seizure app usage has increased during the COVID-19 pandemic and why there remains a need for further data collections. [WATCH TIME: 2 minutes]

Hypoperfusion index was able to estimate the rate of core progression in patients with stroke who had otherwise unclassified progression by reperfusion trial core time criteria.

The study of 251 hospitalized patients with COVID-19 found that biomarkers were elevated to levels that were similar to—or even higher than—those observed in patients with Alzheimer disease.

After a post hoc analysis revealed promising results in a subgroup of younger adults with less disease burden, Ionis has announced that Roche will develop a new phase 2 trial.

The director of the Pediatric Headache Program at CHOP commented on the available therapies for children with migraine, as well as future developments. [WATCH TIME: 4 minutes]

The director of the Pediatric Headache Program at CHOP broke down the treatment of pediatric migraine into 3 different pieces: lifestyle habits, acute treatment, and preventive therapies. [WATCH TIME: 5 minutes]

The trial is a twin of ENSURE-1, which began in November 2021, and is supported by positive clinical data from the phase 2 EMPhASIS trial.

Zhittya Genesis Medicine announced the trial to evaluate its biological drug, FGF-1, which is administered via an intranasal delivery device, in a cohort of individuals with mild to moderate ALS.

The director of the CHOP Pediatric Headache Program commented on the commonality of migraine in children and the need to improve diagnostic practices. [WATCH TIME: 4 minutes]

In cases with reported behavioral variant AD, investigators observed AD-like pattern with relative frontal sparing and a relatively more behavioral variant frontotemporal dementia-like pattern with both posterior and anterior involvement.

The staff epileptologist at Cleveland Clinic’s Epilepsy Center detailed the benefits seizure apps provide for patients with epilepsy, as well as the barriers that limit them. [WATCH TIME: 3 minutes]

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center provided an inside look at the ways MR fingerprinting can provide real-time clinical benefit for physicians and patient care.

Investigators suggest that sex-specific strategies should be invoked to reduce the amount of early stroke deaths after observations suggest that female sex is linked to lower risk of stroke-related events.

David Fischer, MD, neurocritical care fellow at Massachusetts General Hospital and Brigham and Women’s Hospital, outlined findings from a recent study that evaluated hospitalized patients with COVID-19 who were not regaining consciousness.

The professor of neurology at NYU Langone Grossman School of Medicine discussed future research for neurological complications in patients hospitalized with COVID-19 infection. [WATCH TIME: 4 minutes]

Following the publication of data suggesting that EBV is a leading cause of MS, the director of the Ochsner MS Center and an investigator in an EBV-specific therapy clinical trial offered her reaction to the data.

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center discussed opportunities for MR fingerprinting to expand, both in the epilepsy field and in general neurology. [WATCH TIME 3 minutes]

Habits of moderate-to-vigorous exercise were preferentially associated with slower decline of postural and gait stability, and work-related activity levels were primarily associated with slower deterioration of processing speed.

Investigators measured p-tau181 and p-tau231 levels with in-house single molecule array assays and cognition with the Mini-Mental State Examination.

Those who had crossovers of ALS and frontotemporal dementia had structural and functional resemblance to the patterns of damage of those with only behavioral variant frontotemporal dementia.

Becky Tilahun, PhD, a clinical psychologist at Cleveland Clinic, offered insight into a recent study she and colleagues conducted exploring CBT-informed psychotherapy for patients with psychogenic nonepileptic seizures

A recent study found that blood markers of brain damage were higher in patients with COVID-19 than in those with Alzheimer disease. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The research also identified small subcortical cerebral amyloid angiopathy-associated acute ischemic stroke lesions as risk factors for death in these patients.